The Human Microbiome in Health and Disease¶
Chapter 484 | Part 16: Genes, the Environment, and Disease
KEY CLINICAL POINTS¶
- The human microbiome comprises ~1.5–2 kg of microorganisms, with ~1000 bacterial species in the gut and 10,000+ total bacterial species across the body.
- Microbial dysbiosis is linked to chronic diseases (e.g., IBD, obesity, T1D) and immune-mediated conditions (e.g., RA, MS), with the gut microbiota playing a central role.
- Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridioides difficile infection (CDI), with ~85–90% clinical cure rates.
- Diet, antibiotics, and environmental exposures significantly shape the microbiome, with early-life colonization patterns influencing long-term health outcomes.
- Microbial metabolites (e.g., SCFAs, bile acids) modulate immune responses and host physiology, offering therapeutic targets for disease management.
1. DEFINITION & OVERVIEW¶
The human microbiome refers to the collective genetic material of microorganisms (bacteria, viruses, fungi, archaea) inhabiting the human body. It includes ~1000 bacterial species in the gut and 10,000+ total bacterial species across the body. The microbiome interacts with host physiology, influencing immune function, metabolism, and disease susceptibility. The gut microbiota, comprising ~1.5–2 kg of microorganisms, is the most ecologically complex component.
Human Microbiome Project (HMP) Body Site Microbial Composition¶
| Body Site | Dominant Phyla | Key Species |
|---|---|---|
| Stool | Bacteroidetes, Firmicutes | Bacteroides, Ruminococcus |
| Skin | Staphylococcus, Corynebacterium | Staphylococcus epidermidis |
| Vagina | Lactobacillus | Lactobacillus crispatus |
| Oral | Fusobacteria, Actinobacteria | Veillonella, Streptococcus |
1.1 Historical Perspective¶
The microbiome concept evolved from early observations by Leeuwenhoek (1683) and Pasteur (1885), who recognized microbes as essential to health. Modern research began with the Human Microbiome Project (HMP) and MetaHIT, which cataloged microbial communities across body sites.
1.2 Taxonomy and Composition¶
The human microbiome includes five dominant bacterial phyla: Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, and Fusobacteria. Stool samples are the most ecologically rich and accessible for analysis, representing the gut microbiota.
2. EPIDEMIOLOGY¶
The microbiome varies significantly by body site and individual, with ~10,000 bacterial species present in the human body. Interindividual variation is substantial, but core metabolic pathways remain conserved. Environmental factors (e.g., diet, geography) and host genetics influence microbiome composition.
Microbiome Diversity by Age and Body Site¶
| Age Group | Gut Microbiota Diversity | Skin Microbiota Diversity |
|---|---|---|
| Children (<3 years) | High | High |
| Adults (20–40 years) | Moderate | Moderate |
| Elderly (>80 years) | Low | Low |
2.1 Risk Factors¶
Antibiotic use, diet, and lifestyle (e.g., urban vs. rural living) shape the microbiome. Early-life microbial exposure (e.g., mode of delivery, breastfeeding) influences long-term health outcomes.
2.2 Demographics¶
Microbiome diversity declines with age, with elderly individuals showing increased Bacteroides and decreased Lachnospiraceae. Geographic and cultural factors (e.g., Westernization) alter microbial composition.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
The microbiome influences health through immune modulation, metabolic interactions, and pathogen resistance. Dysbiosis (microbial imbalance) contributes to disease by altering immune responses, nutrient absorption, and barrier function. The hygiene hypothesis links reduced microbial exposure to increased autoimmune and allergic diseases.
Microbial Pathways in Disease¶
| Disease | Key Microbial Alterations | Mechanism |
|---|---|---|
| Inflammatory Bowel Disease (IBD) | Reduced Faecalibacterium prausnitzii, increased Enterobacteriaceae | Immunomodulatory imbalance and intestinal inflammation |
| Obesity | Lower Bacteroidetes/Firmicutes ratio, reduced alpha diversity | Altered energy harvest and metabolic signaling |
| Type 1 Diabetes (T1D) | Increased Prevotella copri, reduced Lactobacillus | Autoimmune response and immune dysregulation |
3.1 Microbial-Host Interactions¶
Commensal bacteria produce metabolites (e.g., SCFAs, bile acids) that regulate immune homeostasis and metabolic processes. Dysbiosis disrupts these interactions, leading to inflammation and disease.
3.2 Disease Mechanisms¶
Microbial imbalances are implicated in IBD, obesity, T1D, and cardiovascular disease. For example, altered gut microbiota in IBD reduces butyrate-producing bacteria, increasing intestinal permeability.
4. CLINICAL FEATURES¶
Microbiome-related diseases present with diverse symptoms, including gastrointestinal disturbances, immune-mediated conditions, and metabolic disorders. Key presentations include chronic inflammation, weight changes, and immune dysregulation.
Microbiome-Associated Diseases and Key Features¶
| Disease | Microbial Biomarkers | Clinical Features |
|---|---|---|
| Inflammatory Bowel Disease | Reduced Faecalibacterium prausnitzii | Diarrhea, abdominal pain, weight loss |
| Type 1 Diabetes | Increased Prevotella copri | Autoimmune destruction of pancreatic beta cells |
| Rheumatoid Arthritis | Prevotella copri overabundance | Joint inflammation, systemic immune activation |
4.1 Gastrointestinal Diseases¶
IBD (Crohn’s disease, ulcerative colitis) presents with diarrhea, abdominal pain, and weight loss. Microbial dysbiosis is a central feature, with reduced butyrate-producing bacteria and increased pathogenic species.
4.2 Autoimmune and Inflammatory Diseases¶
RA, MS, and T1D show associations with specific microbial signatures. For example, Prevotella copri is linked to new-onset RA, while gut microbiota alterations contribute to T1D pathogenesis.
5. DIFFERENTIAL DIAGNOSIS¶
Microbiome-related conditions must be differentiated from other systemic diseases. For example, IBD must be distinguished from celiac disease, while autoimmune disorders require differentiation from infectious causes.
5.1 Gastrointestinal Disorders¶
IBD vs. celiac disease: Both present with GI symptoms, but celiac disease is associated with gluten intolerance and specific serological markers (e.g., anti-tTG antibodies).
5.2 Autoimmune vs. Infectious Diseases¶
Autoimmune conditions (e.g., MS) may mimic infections, requiring microbiome analysis and immune profiling to distinguish.
6. INVESTIGATIONS & DIAGNOSIS¶
Microbiome analysis involves stool sampling, sequencing, and functional assays. FMT is used for CDI, while targeted therapies (e.g., probiotics) address specific dysbiosis. Diagnostic criteria include microbial profiling and functional assays.
Diagnostic Criteria for Recurrent CDI¶
| Criteria | Details |
|---|---|
| Prior CDI History | Confirmed by stool toxin assay |
| Antibiotic Use | Recent antibiotic exposure within 3 months |
| Clinical Symptoms | Diarrhea, abdominal pain, fever |
| FMT Efficacy | 85–90% cure rate with donor stool |
6.1 Diagnostic Techniques¶
16S rRNA sequencing, metagenomics, and metabolomics assess microbial composition and function. Stool samples are the primary source, though mucosal biopsies may provide deeper insights.
6.2 Criteria for CDI¶
Diagnosis of recurrent CDI requires confirmation of prior treatment, positive stool toxin assay, and clinical improvement after FMT.
7. MANAGEMENT & TREATMENT¶
Therapies include FMT for CDI, probiotics for dysbiosis, and dietary interventions to modulate microbial composition. Targeted antibiotics and prebiotics may also be used to restore balance.
FMT Administration Routes and Efficacy¶
| Route | Cure Rate | Notes |
|---|---|---|
| Colonoscopy | 90–95% | Most effective for lower GI delivery |
| Nasogastric Tube | 80–85% | Lower efficacy than colonoscopy |
| Oral Capsules | 70–75% | Requires adherence to pre-FMT diet |
7.1 Fecal Microbiota Transplantation (FMT)¶
FMT is the gold standard for recurrent CDI, with donor stool administered via enema, colonoscopy, or capsules. Success rates exceed 85% in clinical trials.
7.2 Probiotics and Prebiotics¶
Probiotics (e.g., Lactobacillus, Bifidobacterium) and prebiotics (e.g., inulin) support beneficial microbes. They are used for IBS, antibiotic-associated diarrhea, and immune modulation.
8. PROGNOSIS & COMPLICATIONS¶
Microbiome-based therapies improve outcomes in IBD, obesity, and autoimmune diseases. However, complications include antibiotic resistance, immune dysregulation, and donor-specific adverse effects.
8.1 Long-Term Outcomes¶
Successful microbiome modulation can reverse disease progression in IBD and reduce T1D incidence. However, long-term stability requires sustained microbial balance.
9. SPECIAL CONSIDERATIONS¶
Pregnancy, pediatrics, and elderly populations require tailored microbiome management. For example, maternal microbiota influences neonatal colonization, while elderly patients face age-related microbiome shifts.
10. KEY POINTS & CLINICAL PEARLS¶
The microbiome is a critical determinant of health, with dysbiosis linked to chronic diseases. FMT is effective for CDI, while probiotics and dietary interventions address specific microbial imbalances. Understanding host-microbe interactions is essential for personalized therapeutic strategies.